Cytosinlab Therapeutics Co. Ltd. has divulged protein arginine N-methyltransferase 1 (PRMT1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorder, malaria, AIDS, gout, diabetes, renal failure and cocaine dependency, among others.